“Pharma Bro” Martin Shkreli’s former company and former business partner agreed to settle legal claims arising from the company’s purchase of and 4,000% price increase on the drug Daraprim.

“Pharma Bro’s” ex-Company and ex-Partner Settling Claims Arising from Daraprim “Scheme,” FTC Says

“Pharma Bro” Martin Shkreli’s former company and former business partner agreed Tuesday to settle legal claims brought against them by the U.S. and seven state governments arising from the company’s purchase of and 4,000% price increase on the drug Daraprim, which is used to treat toxoplasmosis in patients with HIV.

The U.S. Federal Trade Commission (FTC) and its state co-plaintiffs—New York, California, Illinois, North Carolina, Ohio, Pennsylvania, and Virginia—will get up to $40 million from Vyera (formerly Turing) Pharmaceuticals and its parent company Phoenixus AG. Shkreli’s ex-partner Kevin Mulleady “will generally be banned from working for, consulting for, or controlling a pharmaceutical company for seven years,” according to the FTC.

“Pharma Bro” Martin Shkreli’s former company and former business partner agreed Tuesday to settle legal claims brought against them by the U.S. and seven state governments arising from the company’s purchase of and 4,000% price increase on the drug Daraprim, which is used to treat toxoplasmosis in patients with HIV.

Please Login or Become a Paid Subscriber to View this Content

If you are already a paid subscriber, please follow the steps below.
If you are not yet a paid subscriber, please Subscribe now.
For questions about subscriptions or technical assistance, please contact Reshma Eggleston at reshma.eggleston@340breport.com.
« Read Previous Read Next »
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors
×

*Sign up for news summaries and alerts from 340B Report

Site Footer